# Dose-Response Study to Evaluate the Effect of BKR-017 on Insulin Resistance and Other Metabolic Parameters in Type 2 Diabetes Patients

> **NCT04673656** · NA · COMPLETED · sponsor: **BioKier Inc.** · enrollment: 60 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DIETARY_SUPPLEMENT:** BKR-017

## Key facts

- **NCT ID:** NCT04673656
- **Lead sponsor:** BioKier Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-18
- **Primary completion:** 2022-12-10
- **Final completion:** 2023-02-07
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2023-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04673656

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04673656, "Dose-Response Study to Evaluate the Effect of BKR-017 on Insulin Resistance and Other Metabolic Parameters in Type 2 Diabetes Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04673656. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*